βIII‐tubulin suppression enhances the activity of Amuvatinib to inhibit cell proliferation in c‐Met positive non‐small cell lung cancer cells

Non‐Small Cell Lung Carcinoma (NSCLC) remains a leading cause of cancer death. Resistance to therapy is a significant problem, highlighting the need to find new ways of sensitising tumour cells to therapeutic agents. βIII‐tubulin is associated with aggressive tumours and chemotherapy resistance in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Brayford, Simon, Duly, Alastair, Teo, Wee Siang, Dwarte, Tanya, Gonzales‐Aloy, Estrella, Ma, Zerong, McVeigh, Laura, Failes, Timothy W., Arndt, Greg M., McCarroll, Joshua A., Kavallaris, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972117/
https://www.ncbi.nlm.nih.gov/pubmed/35946957
http://dx.doi.org/10.1002/cam4.5128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972117/
https://www.ncbi.nlm.nih.gov/pubmed/35946957
http://dx.doi.org/10.1002/cam4.5128

Ejemplares similares